Biogen Idec's George Scangos on a Failed ALS Drug Trial

The CEO of Biogen Idec on having to give up on a potentially lucrative drug for Lou Gehrig’s disease
Illustration by Jimmy Turrell

We had a drug called dexpramipexole—dex, for short—that was in development for ALS, or Lou Gehrig’s disease. It’s a devastating disease that often strikes young people. From diagnosis to death takes about three years. They stop being able to walk, then stop being able to move, and eventually they can’t breathe. All this time, their cognitive functions are completely unimpaired. There’s a person trapped inside this body that doesn’t work.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.